🇺🇸 FDA
Patent

US 11427838

Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders

granted A61KA61K35/34A61K38/465

Quick answer

US patent 11427838 (Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K35/34, A61K38/465